Scancell Holdings Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Scancell Holdings

Dividende od Scancell Holdings su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Scancell Holdings tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Scancell Holdings su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Scancell Holdings mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Scancell Holdings Aktienanalyse

Шта ради Scancell Holdings?

Scancell Holdings PLC is a biotechnology company specializing in the development of immunotherapies for cancer. The company was founded in 1997 and is headquartered in Nottingham, United Kingdom. Scancell's goal is to improve the lives of patients with cancer by developing innovative therapies that selectively activate the body's immune system. Scancell's business model is based on the research, development, and commercialization of immunotherapies. The company has developed a platform technology called Modified Vaccinia Ankara (MVA), which is a widely used virus in vaccine research and development. Scancell uses this platform technology to develop vaccines that selectively activate the immune system against cancer cells. The company works closely with academic partners and other biotech companies. The company has two main divisions: Scancell Immunotherapy and Scancell Biotherapeutics. Under the Scancell Immunotherapy division, the company develops cancer vaccines. Scancell is actively working on the development of two main products: SCIB1 and Modi-1. SCIB1 is an immunotherapy based on a DNA-based vaccine that activates the immune system to attack cancer cells. This vaccine has been studied in various clinical trials and has shown promising results. SCIB1 has been tested in a Phase II study on patients with advanced melanoma and has triggered a strong immune response in most patients. The company is now working on further developing SCIB1 in clinical trials. Modi-1 is an immunotherapy based on a novel technology called Modified T-cells. These are engineered T-cells that compel the immune system to recognize and attack cancer cells. Modi-1 is still in the development phase and has not yet been tested in clinical trials. Under the Scancell Biotherapeutics division, the company develops antibodies for cancer treatment. The company focuses on developing antibodies that target specific cancer antigens. Scancell has already developed several promising antibody candidates, including AvidiMabTM, an antibody candidate against the CD98 receptor, which is overexpressed in many cancer cells. Scancell is currently listed on the London Stock Exchange and has a market capitalization of around £250 million. The company also has a strong pipeline of products in development and is actively working to realize their potential. Scancell has a strong partnership with AstraZeneca, one of the world's largest pharmaceutical companies, to support its research and development activities. In summary, Scancell is an emerging biotech company specializing in the development of immunotherapies for cancer. The company has a strong pipeline of products in development and works closely with leading scientists and academic institutions. Scancell is a promising company that offers exciting opportunities for both investors and patients. Scancell Holdings je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Scancell Holdings akciji

Kolika je dividenda koju isplaćuje Scancell Holdings?

U poslednjih 12 meseci, Scancell Holdings je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Scancell Holdings će verovatno isplatiti dividendu od 0 GBP.

Kolika je dividendna prinosa za Scancell Holdings?

Dividendski prinos od Scancell Holdings trenutno iznosi .

Kada Scancell Holdings isplaćuje dividendu?

Scancell Holdings isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Scancell Holdings?

Scancell Holdings je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Scancell Holdings?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 GBP. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Scancell Holdings?

Scancell Holdings se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Scancell Holdings kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Scancell Holdings od 28. 6. 2024. u iznosu od 0 GBP, morali ste da imate akciju u depou pre Ex-dana 28. 6. 2024..

Kada je Scancell Holdings poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 28. 6. 2024..

Kolika je bila dividenda od Scancell Holdings u godini 2023?

U godini 2023 kompanija Scancell Holdings je isplatila 0 GBP kao dividende.

U kojoj valuti Scancell Holdings isplaćuje dividendu?

Dividende od Scancell Holdings se isplaćuju u GBP.